Here's a LinkedIn post that sounds like a genuine student moment:

We were in the middle of a lecture on Recombinant DNA Technology when he paused and said:

80 human pituitary glands. For one unit.

Let that sink in.

Children with growth hormone deficiency were being treated with hormone painstakingly harvested from cadavers - brain by brain, gland by gland. The logistics alone were staggering. Hospitals, morgues, and researchers had to coordinate the collection, extraction, and purification of tissue from deceased donors on a massive scale, all to produce a treatment that was, by modern standards, heartbreakingly scarce.

And then came the darker chapter - some batches were contaminated with prions, leading to cases of Creutzfeldt-Jakob disease in patients who had received cadaver-derived GH. A treatment meant to help children grow was, in some cases, fatal.

That changed in 1985 when recombinant DNA technology allowed scientists to produce biosynthetic human growth hormone - the same protein, made in bacteria, in virtually unlimited quantities, with no cadaveric risk.

One lecture. One statistic. A complete reframe of what biotechnology actually means in human terms.

We talk about recombinant DNA as a technique - restriction enzymes, plasmids, expression vectors. But behind every such breakthrough is a "before" that reminds you why it mattered.

Science doesn't just advance. Sometimes, it rescues.